Cargando…
The NRF2 transcriptional target, OSGIN1, contributes to monomethyl fumarate-mediated cytoprotection in human astrocytes
Dimethyl fumarate (DMF) is indicated for the treatment of relapsing multiple sclerosis and may exert therapeutic effects via activation of the nuclear factor (erythroid-derived 2)-like 2 (NRF2) pathway. Following oral DMF administration, central nervous system (CNS) tissue is predominantly exposed t...
Autores principales: | Brennan, Melanie S., Matos, Maria F., Richter, Karl E., Li, Bing, Scannevin, Robert H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5299414/ https://www.ncbi.nlm.nih.gov/pubmed/28181536 http://dx.doi.org/10.1038/srep42054 |
Ejemplares similares
-
Dimethyl Fumarate and Monoethyl Fumarate Exhibit Differential Effects on KEAP1, NRF2 Activation, and Glutathione Depletion In Vitro
por: Brennan, Melanie S., et al.
Publicado: (2015) -
Pharmacokinetics and Bioavailability of Monomethyl Fumarate Following a Single Oral Dose of Bafiertam™ (Monomethyl Fumarate) or Tecfidera(®) (Dimethyl Fumarate)
por: Lategan, Thomas W., et al.
Publicado: (2021) -
Monomethyl fumarate promotes Nrf2-dependent neuroprotection in retinal ischemia-reperfusion
por: Cho, Hongkwan, et al.
Publicado: (2015) -
Dimethyl Fumarate and Monomethyl Fumarate Promote Post-Ischemic Recovery in Mice
por: Yao, Yang, et al.
Publicado: (2016) -
Monomethyl fumarate prevents alloimmune rejection in mouse heart transplantation by inducing tolerogenic dendritic cells: Monomethyl fumarate prevents alloimmune rejection
por: Chen, Juntao, et al.
Publicado: (2023)